Copaxone stay rejected and balugrastim withdrawn

Biosimilars/General | Posted 06/12/2013 post-comment0 Post your comment

Teva Pharmaceutical Industries (Teva) had its request for a stay of an appeals court ruling on its blockbuster drug Copaxone (glatiramer acetate) rejected, and that it had withdrawn its application for approval of balugrastim (granulocyte colony-stimulating factor [G-CSF]).

picture04

On 13 November 2013, US Supreme Court Chief Justice John Roberts declined a request from Teva for a stay of an appeals court ruling made in July 2013 that invalidated several of Teva’s patents on Copaxone, including one that protected the drug until September 2015. The decision opened Teva’s blockbuster multiple sclerosis drug to competition from generics starting in May 2014 [1].

Teva had asked the US Supreme Court to stay the ruling while the company prepares to file a petition seeking the high court’s review, but the court announced that Chief Justice John Roberts had rejected the request and did not provide further explanation.

On 18 November 2013, Teva announced that it had withdrawn its balugrastim Biologic License Application (BLA) from the US Food and Drug Administration (FDA) review process following ongoing consultation with the agency. Teva said that FDA has agreed to work with the company in designing any additional studies that may be required in support of the BLA for balugrastim.

Balugrastim has been evaluated in phase III clinical trials for its ability to reduce the duration of severe neutropenia in breast cancer patients undergoing chemotherapy. Neutropenia is a condition in which the number of white blood cells is decreased, leaving patients more susceptible to potentially life-threatening bacterial infections. The drug is seen as comparable, and therefore a potential competitor, to Amgen’s Neulasta (pegfilgrastim).

Related article

Teva asks FDA to delay approval of Biogen’s MS drug

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Teva loses fight against generic glatiramer acetate [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Dec 6]. Available from: www.gabionline.net/Generics/News/Teva-loses-fight-against-generic-glatiramer-acetate

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Reuters

comment icon Comments (0)
Post your comment
Related content
Biosimilars approved in Paraguay
DINAVISA V21J15LT
Biosimilars/General Posted 15/10/2021
Biosimilars approved in Cuba
CECMED V21J07LT
Biosimilars/General Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010